People · Operator
Named in public records as an officer, director or promoter · active 2010–2018 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Anavex Life Sciences Corp. | — | Biotechnology | Series A | $10.5M | $361.5M | 2010 |
| TheraPten Biosciences Inc. | — | Biotechnology | Seed | $2.0M | $66.6M | 2018 |
| Scythian Biosciences Inc. | — | Biotechnology | Pre-Seed | $462K | $9.4M | 2014 |
Harvey Lalach at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Harvey Lalach on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Cameron Durrant | 1 | 5 |
| Jonathan Gilbert | 1 | 4 |
| Yiannis Monovoukas | 1 | 3 |
| Jerome Gilbert | 1 | 2 |
| Allan Cohen | 1 | 2 |
| David Tousley | 1 | 2 |
| Mo Fazil | 1 | 2 |
| Christopher U. Missling | 1 | 1 |
| Kyriakoulis Paganis | 1 | 1 |
| Athanosios U. Skarpelos | 1 | 1 |
| Alison Ayers | 1 | 1 |
| David Schrader | 1 | 1 |
| Michael Petter | 1 | 1 |
| Athanasios Alevizopoulos | 1 | 1 |
| Harvey Lach | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.